Haemonetics (HAE) Misses Q4 EPS by 9c

Haemonetics (NYSE: HAE) reported Q4 EPS of $0.37, $0.09 worse than the analyst estimate of $0.46. Revenue for the quarter came in at $243.2 million versus the consensus estimate of $245.08 million.

For earnings history and earnings-related data on Haemonetics (HAE) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Candel Therapeutics, Inc. (CADL) Misses Q2 EPS by 29c
• MeiraGTx Holdings plc (MGTX) Tops Q2 EPS by 202c